FDA OKs PML Risk Test for Patients on Tysabri
(MedPage Today) — The FDA has approved the first test for assessing the risk of progressive multifocal leukoencephalopathy in patients on natalizumab (Tysabri).
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com